Current stock page

Catalysts

NUVB Stock Catalysts

Earnings · Growth Drivers · Events · AIQ Catalyst

HealthcareBiotechnologyScore data as of Sep 4, 2026

NUVB

Catalysts
Nuvation Bio Inc.
Healthcare· Biotechnology
AIQ Score
NeutralAIQ Edge 4/10
Low Priority
In Line With Peers
Score data as of Sep 4, 2026
Last price
$6.81
+$0.04 (+0.59%)
Latest market quote
Momentum66
Value34
Quality45
Risk Resilience43
Sentiment
View financial data

Stock Catalyst Board

Earnings timing, analyst expectations, news pressure, growth drivers, events, and AIQ Catalyst context.

Next earnings
Nov 2, 2026

Upcoming reporting date available for this company.

AIQ Catalyst
AIQ 47/100

Momentum 66/100 and sentiment before the next covered event.

Recent coverage
5 articles

Updated Sep 6, 2026 · Sentiment 16.23%

Earnings History And Surprises

See whether reported EPS and revenue have consistently exceeded or missed analyst expectations.

Earnings Expectations And Results

Compare what analysts expected with what the company reported across recent quarters.

Momentum 66/100AIQ Edge 4/10 In Line With Peers
Beat rate
25%
2 of 8 reported periods
Average surprise
+14.1%
Across covered historical reports
Latest result
-5.9%
Aug 6, 2026
EPS estimate versus actual
Actual bars are colored by beat, inline result, or miss.
Earnings history
Report dateFiscal periodEPS estimateEPS actualEPS surpriseRevenue estimateRevenue actual
Aug 6, 2026-$0.14-$0.15-5.9%$27.03M$31.69M
May 4, 2026-$0.03$0.01+135.7%$66.22M$83.23M
Mar 2, 2026-$0.11-$0.11+0.0%$37.81M$41.87M
Nov 3, 2025-$0.17-$0.16+5.9%$36.82M$13.12M
Aug 7, 2025-$0.17-$0.17+0.0%$3.62M$4.83M
May 7, 2025-$0.16-$0.16+0.0%$357.14K$3.08M
Mar 6, 2025-$0.14-$0.15-7.1%$833.33K$5.71M
Nov 6, 2024-$0.13-$0.15-15.4%$727K

Analyst Forecast And Price Targets

Wall Street consensus, rating distribution, and the current 12-month target range.

Analyst ratings
Buy
10
Buy
1
Hold
12-month analyst target
$20.00
+193.69% versus current price
Based on 2 analyst observations. Targets are estimates, not predictions.
Low target
$19.00
+179.00% vs latest price
Average target
$20.00
+193.69% vs latest price
High target
$21.00
+208.37% vs latest price

Event Read

Catalysts should explain what can change the setup, when it might happen, and which AIQ component would move first.

Current event setup

Event dateNov 2, 2026

Next known earnings or reporting date.

EPS estimate-$0.12

Current analyst expectation for the upcoming report.

Revenue estimate$35.77M

Current analyst expectation for the upcoming report.

Sentiment score

News pressure around the setup.

Momentum score66

Where event reaction would show up first.

AIQ score47/100

Composite decision read before event confirmation.

Analyst context

Consensus
Buy
Analysts
2
Average target
$20.00
Target upside
193.69%
Target range
$19.00 - $21.00
90-day revisions
-157

News And Sentiment

Recent company coverage, scored where source sentiment is available.

Positive
2
Neutral
2
Negative
1
seekingalpha.com · Aug 26, 2026

Nuvation: Why I'm Downgrading To Hold Despite Progress On NSCLC And Glioma Fronts (NUVB)

Nuvation Bio Inc. downgraded to Hold after a 200% run. Click for this updated look at NUVB and see where I see the stock going next.

finance.yahoo.com · Aug 8, 2026

Nuvation Bio Q2 Earnings Call Highlights

Nuvation Bio (NYSE:NUVB) reported second-quarter total revenue of $31.7 million, including $23.2 million in net U.S. product revenue from IBTROZI, as the company said use of the ROS1-targeted lung cancer therapy continued to shift toward first-line patients. IBTROZI revenue increased 25% from the f

seekingalpha.com · Aug 6, 2026

Nuvation Bio Inc. (NUVB) Q2 2026 Earnings Call Transcript

Nuvation Bio Inc. (NUVB) Q2 2026 Earnings Call August 6, 2026 8:00 AM EDTCompany ParticipantsRobert DeVita - Vice President of Corporate Development &...

zacks.com · Aug 6, 2026

Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue Estimates

Nuvation Bio (NUVB) delivered earnings and revenue surprises of 0.00% and +16.86%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

zacks.com · Jul 30, 2026

Nuvation Bio Inc. (NUVB) Expected to Beat Earnings Estimates: Should You Buy?

Nuvation Bio (NUVB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Open full news and sentiment

NUVB Catalysts FAQ

What are the next catalysts for NUVB stock?

NUVB's next stock catalysts can include earnings, guidance, analyst ratings, price-target changes, estimate revisions, product updates, regulatory events, contracts, or sector developments. Use this page to connect those events with AIQ and market context.

What upcoming events could move NUVB stock?

Upcoming events that could move NUVB include earnings reports, management commentary, estimate changes, major news, and market-wide sector catalysts.

How could NUVB's next earnings report affect the stock?

NUVB's next earnings report could affect the stock by changing revenue expectations, EPS estimates, guidance, analyst ratings, price targets, estimate revisions, and momentum.

What could drive NUVB stock higher?

NUVB could move higher if earnings, guidance, demand trends, analyst expectations, or AIQ momentum improve relative to what the market already expects.

What events could hurt NUVB stock?

NUVB could be hurt by weaker guidance, negative estimate revisions, margin pressure, adverse news, regulatory issues, or a sector-wide risk-off move.